Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12

•The effect on multiple components of the peripheral immunome from the first-in-human trial of the tumor targeting immune-cytokine NHS-IL12.•Greater immune activation is seen with both a higher dose and a more frequent dosing schedule of NHS-IL12.•Immune analytes of patients at both baseline and ear...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2023-03, Vol.116, p.109736, Article 109736
Main Authors: Toney, Nicole J., Gatti-Mays, Margaret E., Tschernia, Nicholas P., Strauss, Julius, Gulley, James L., Schlom, Jeffrey, Donahue, Renee N.
Format: Article
Language:English
Subjects:
Cancer
Humans
Immunocytokine
Immunotherapy
Interleukin 12
Ki-67 Antigen
Killer Cells, Natural
Neoplasms - drug therapy
NHS-IL12
Peripheral immunome
State Medicine
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The effect on multiple components of the peripheral immunome from the first-in-human trial of the tumor targeting immune-cytokine NHS-IL12.•Greater immune activation is seen with both a higher dose and a more frequent dosing schedule of NHS-IL12.•Immune analytes of patients at both baseline and early after treatment with NHS-IL12 associate with clinical response.•These findings will help guide future schedule and dosing regimens of NHS-IL12. The immunocytokine NHS-IL12 delivers IL-12 to the tumor microenvironment by targeting DNA/histones in necrotic areas. The first-in-human clinical trial administered NHS-IL12 subcutaneously in 59 patients treated every-four weeks (Q4W), with a maximum tolerated dose of 16.8 mcg/kg. The phase I study was expanded to include a high-exposure cohort that received bi-weekly treatment (Q2W) with two dose levels of NHS-IL12: 12.0 mcg/kg and 16.8 mcg/kg. Here, patients given NHS-IL12 were analyzed both prior to and early after treatment for effects on 10 serum soluble analytes, complete blood counts, and 158 peripheral immune subsets. Higher levels of immune activation were seen with a dose of 16.8 mcg/kg versus 12.0 mcg/kg in patients in the high-exposure cohort, as evidenced by greater increases in serum IFNγ, TNFα, and soluble PD-1, and greater increases in frequencies of peripheral ki67+mature natural killer (NK), CD8+ T, and NKT cells. Greater immune activation was also seen in the Q2W versus Q4W cohort, as demonstrated by greater increases in pro-inflammatory serum analytes, ki67+CD8+T, NK, and NKT cells, intermediate monocytes, and a greater decrease in CD73+T cells. Specific immune analytes at baseline including lower levels of monocytes and plasmacytoid dendritic cells, and early changes after treatment such as an increase in refined NK cell subsets and total CD8+ T cells, associated with better clinical response. These findings may help to guide future schedule and dosing regimens of clinical studies of NHS-IL12 as monotherapy and in combination therapies.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2023.109736